HENDERSON, Nev. - Zura Bio Limited (NASDAQ:ZURA) announced that the design of its Phase 2 TibuSURE clinical trial has been accepted for poster presentation at the Systemic Sclerosis World Congress ...
Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and ...
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress Zura Bio Limited (Nasdaq: ZURA) ...
HENDERSON, Nev., March 05, 2026--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve ...
Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with ...
A live webcast of the Leerink Global Healthcare Conference fireside chat will be available in the Investors section of the Company’s website under News & Events. A replay will be accessible for at ...
Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and ...
Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results